## **PRESS**RELEASE



## **Shionogi to Announce Personnel Reassignment**

**OSAKA, Japan, March 13, 2023 -** Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.) announced that Shionogi will implement the following personnel reassignment as of April 1, 2023.

1. Personnel Reassignments (Effective; April 1, 2023)

New Position	Name	Present Position					
R&D Supervisory Unit Drug Development and Regulatory Science Division							
Vice President, Medical Science Department	Takuhiro Sonoyama	Medical Science Department					
Senior Director, Biostatistics Center	Takahiro Hasegawa	Biostatistics Center					

## **Forward-Looking Statements**

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

## **For Further Information, Contact:**

SHIONOGI Website Inquiry Form: <a href="https://www.shionogi.com/global/en/contact.html">https://www.shionogi.com/global/en/contact.html</a>

				Corporate Executive Meeting		
The Annual General Meeting of Shareholders —		Board of Directors			→	
		Chief Executive Officer and Representative Director		Compliance Committee		
			<u>_</u>		J	
	Board of Auditors					
R&D Supervisory Unit		Research Division		Laboratory for Drug Discovery and Disease Research		
	<del></del>		<u> </u>	Laboratory for Medicinal Chemistry Research		
				Laboratory for Drug Discovery and Development		
				API R&D Laboratory		
				Formulation R&D Laboratory		
				Intellectual Property Department		
•						
		Drug Development and Regulatory Science Division		Project Management Department		
				Clinical Research Department		
				Medical Science Department		
				Regulatory Affairs Department		
				Pharmacovigilance Department		r
						Biostatistics Center
					i	
		Biopharmaceutical Research Division		Laboratory for Bio-Drug Discovery		
				Laboratory for Bio-Modality Research		
				Analysis and Evaluation Laboratory		
					i	
				Business Development Department		
				Investment Strategy Department		
		DI		D	i	
Healthcare Business Supervisory Unit		Pharmaceutical Commercial Division		Promotion Department - Region 1		
				Promotion Department - Region 2		
				Promotion Department - Region 3		
				Promotion Department - Region 4		
				Promotion Department - Region 5		
				Distribution Management Department		0.1. 0.00
						Sales Promotion Office
						Specialty Product Office
		The state of the s		N. D. L. D. C. D. C. C.	1	
		Integrated Disease Care Division		New Product Planning Department		Devil Control
				Medical Affairs Department		Drug Information Center
				Corporate Social Responsibility Department		Office for Children's Bright Future
				New Business Promotion Department		Office for Stewardship to Proper Use of Medicine
				New business Fromotion Department		Academia Collaboration Office
						Academia Collaboration Office
				Government Affairs Department	İ	
				Vaccine and Diagnostic Drug Department		Diagnostic Drug Office
				vaccine and Diagnostic Drug Department		Partnership Promotion Office
				Tokyo Branch Office		Farthership Fromotion Office
				Tokyo Bialicii Office		
Supply Supervisory Unit		Global Business Division		Global Business Department		
Supply Supervisory Offic		Global Basiliess Division		Global Supply Chain Strategy Department		
				and a supply and a stategy department	!	
Corporate Supervisory Unit		Corporate Strategy Division		Corporate Planning Department		
			<del>'</del>	Finance & Accounting Department		Business Administration Office
				Corporate Communications Department		business / turninstructori ornec
				Corporate Secretariat		
		Administration Division		Human Resources Department		Human Capital Strategy Office
			<del></del>	,		Career Development Office
				Value Chain Support Department		R&D Support Office
						Healthcare Business Support Office
				General Administration Department		
				Legal Affairs Department		
				Sustainability Management Department		
					•	
	-	DX Promotion Division		IT & Digital Solution Department		
				Data Science Department		
					•	
		Corporate Quality Assurance and Ethics & Compliance Management Division		Quality Assurance Department		
		(General Marketing Compliance Officer)				Promotional Compliance Office
					•	·
				Internal Control Department		